NYSE:PKI - PerkinElmer Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$95.07 -2.43 (-2.49 %)
(As of 03/22/2019 11:14 AM ET)
Previous Close$97.50
Today's Range$94.91 - $97.04
52-Week Range$70.83 - $98.33
Volume134,944 shs
Average Volume506,314 shs
Market Capitalization$10.53 billion
P/E Ratio26.34
Dividend Yield0.29%
Beta1.25
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries; and laboratory services. In addition, this segment offers a suite of solutions comprising reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market. The Diagnostics segment provides instruments, reagents, and software test and screen products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used in diagnosing genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for use in applications covering oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. has a collaboration agreement with Helix and Precipio, Inc. The company was founded in 1931 and is headquartered in Waltham, Massachusetts.

Receive PKI News and Ratings via Email

Sign-up to receive the latest news and ratings for PKI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorComputer and Technology
CUSIP71404610
Phone781-663-6900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.78 billion
Cash Flow$5.4481 per share
Book Value$23.24 per share

Profitability

Net Income$237.93 million

Miscellaneous

Employees12,500
Market Cap$10.53 billion
Next Earnings Date4/29/2019 (Estimated)
OptionableOptionable

PerkinElmer (NYSE:PKI) Frequently Asked Questions

What is PerkinElmer's stock symbol?

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

How often does PerkinElmer pay dividends? What is the dividend yield for PerkinElmer?

PerkinElmer declared a quarterly dividend on Thursday, January 24th. Shareholders of record on Friday, April 19th will be given a dividend of $0.07 per share on Friday, May 10th. This represents a $0.28 annualized dividend and a dividend yield of 0.29%. The ex-dividend date of this dividend is Wednesday, April 17th. View PerkinElmer's Dividend History.

How were PerkinElmer's earnings last quarter?

PerkinElmer, Inc. (NYSE:PKI) announced its earnings results on Thursday, January, 31st. The medical research company reported $1.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.16 by $0.02. The medical research company earned $756.35 million during the quarter, compared to the consensus estimate of $746.15 million. PerkinElmer had a return on equity of 15.89% and a net margin of 8.56%. During the same quarter in the previous year, the company posted $0.97 EPS. View PerkinElmer's Earnings History.

When is PerkinElmer's next earnings date?

PerkinElmer is scheduled to release their next quarterly earnings announcement on Monday, April 29th 2019. View Earnings Estimates for PerkinElmer.

What guidance has PerkinElmer issued on next quarter's earnings?

PerkinElmer issued an update on its FY19 earnings guidance on Thursday, January, 31st. The company provided earnings per share guidance of $4.00-4.05 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.03.

What price target have analysts set for PKI?

13 Wall Street analysts have issued 1-year price objectives for PerkinElmer's stock. Their predictions range from $44.50 to $104.00. On average, they expect PerkinElmer's share price to reach $80.5717 in the next year. This suggests that the stock has a possible downside of 15.3%. View Analyst Price Targets for PerkinElmer.

What is the consensus analysts' recommendation for PerkinElmer?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 9 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PerkinElmer.

Has PerkinElmer been receiving favorable news coverage?

News stories about PKI stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. PerkinElmer earned a news impact score of 0.8 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an impact on the company's share price in the near term.

Who are some of PerkinElmer's key competitors?

What other stocks do shareholders of PerkinElmer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include Celgene (CELG), Micron Technology (MU), Honeywell International (HON), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), General Electric (GE), Square (SQ), NVIDIA (NVDA), Illumina (ILMN) and salesforce.com (CRM).

Who are PerkinElmer's key executives?

PerkinElmer's management team includes the folowing people:
  • Mr. Robert F. Friel, Chairman & CEO (Age 63)
  • Dr. Prahlad R. Singh, Pres & COO (Age 54)
  • Mr. James M. Mock, Sr. VP & CFO (Age 42)
  • Mr. Joel S. Goldberg, Sr. VP of Admin., Gen. Counsel & Sec. (Age 50)
  • Mr. James Corbett, Exec. VP and Pres of Discovery & Analytical Solutions (Age 56)

Who are PerkinElmer's major shareholders?

PerkinElmer's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.29%), Massachusetts Financial Services Co. MA (3.39%), King Luther Capital Management Corp (2.26%), Geode Capital Management LLC (1.37%), FMR LLC (1.10%) and Northern Trust Corp (0.96%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Frank Anders Wilson, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett and Robert F Friel. View Institutional Ownership Trends for PerkinElmer.

Which institutional investors are selling PerkinElmer stock?

PKI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, State Treasurer State of Michigan, Impax Asset Management Group plc, FMR LLC, First National Bank of Omaha, Lord Abbett & CO. LLC, Robecosam AG and Barclays PLC. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett and Robert F Friel. View Insider Buying and Selling for PerkinElmer.

Which institutional investors are buying PerkinElmer stock?

PKI stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, BlackRock Inc., Massachusetts Financial Services Co. MA, Geode Capital Management LLC, Public Employees Retirement System of Ohio, Thrivent Financial for Lutherans, First Citizens Bank & Trust Co. and Bank of America Corp DE. View Insider Buying and Selling for PerkinElmer.

How do I buy shares of PerkinElmer?

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is PerkinElmer's stock price today?

One share of PKI stock can currently be purchased for approximately $95.07.

How big of a company is PerkinElmer?

PerkinElmer has a market capitalization of $10.53 billion and generates $2.78 billion in revenue each year. The medical research company earns $237.93 million in net income (profit) each year or $3.61 on an earnings per share basis. PerkinElmer employs 12,500 workers across the globe.

What is PerkinElmer's official website?

The official website for PerkinElmer is http://www.perkinelmer.com.

How can I contact PerkinElmer?

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected]


MarketBeat Community Rating for PerkinElmer (NYSE PKI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  404 (Vote Outperform)
Underperform Votes:  421 (Vote Underperform)
Total Votes:  825
MarketBeat's community ratings are surveys of what our community members think about PerkinElmer and other stocks. Vote "Outperform" if you believe PKI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PKI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel